Ikena Oncology Terminates Bristol Myers Squibb Deal for IK-750

Ticker: IMA · Form: 8-K · Filed: May 28, 2024 · CIK: 1835579

Ikena Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyIkena Oncology, INC. (IMA)
Form Type8-K
Filed DateMay 28, 2024
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.001, $1.2 million
Sentimentneutral

Sentiment: neutral

Topics: collaboration-termination, drug-development, licensing

Related Tickers: BMY

TL;DR

Ikena Oncology takes back IK-750 from BMS, costs incurred from termination.

AI Summary

On May 23, 2024, Ikena Oncology, Inc. announced the termination of its collaboration and license agreement with Bristol Myers Squibb for the development of IK-750. As a result, Ikena Oncology will regain all rights to IK-750 and will incur costs associated with the exit or disposal activities related to this termination.

Why It Matters

This termination means Ikena Oncology will now manage the development of IK-750 independently, potentially impacting its future research and development strategy and resource allocation.

Risk Assessment

Risk Level: medium — The termination of a significant collaboration and the associated costs introduce financial and strategic risks for Ikena Oncology.

Key Players & Entities

FAQ

What is the primary reason for the termination of the agreement with Bristol Myers Squibb?

The filing does not explicitly state the primary reason for the termination, only that the agreement has been terminated.

What happens to the rights of IK-750 after the termination?

Ikena Oncology, Inc. will regain all rights to IK-750.

When was the earliest event reported in this filing?

The earliest event reported was on May 23, 2024.

What type of costs will Ikena Oncology incur due to this termination?

Ikena Oncology will incur costs associated with exit or disposal activities related to the termination.

What is the principal executive office address for Ikena Oncology?

The address is 645 Summer Street, Suite 101, Boston, Massachusetts 02210.

Filing Stats: 1,053 words · 4 min read · ~4 pages · Grade level 11.8 · Accepted 2024-05-28 16:24:07

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "may," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements, other than historical facts, including statements regarding the Company's expectations related to the Restructuring Plan and the Board's exploration of strategic options are forward-looking statements. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors, including but not limited to the important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and its other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements represent management's estimates as of this date and the Company undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Ikena Oncology, Inc. Press Release, dated May 28, 2024 99.2 Ikena Oncology, Inc. Corporate Presentation 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ikena Oncology, Inc. Date: May 28, 2024 By: /s/ Mark Manfredi Mark Manfredi, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing